Reveal Banner _468
Reveal Your MR Imaging Potential with Elucirem™ (gadopiclenol) injection
Submit Images Now
Program Decscription
Introducing the Reveal Image Challenge supported by Guerbet; providing US MR imaging professionals with an opportunity to reveal their MR imaging potential with Elucirem™ (gadopiclenol) injection. See Guerbet Press Release.
Submitted MRI images using Elucirem™ will be consideration, in an ‘Image of the Month’ selection campaign; leading to an ‘Image of the Year’ Reveal Event at RSNA 2023. Exciting rewards include social media exposure and publication on appliedradiology.com. Additionally, images may appear in Guerbet’s marketing and educational materials.
Participants are encouraged to showcase their imaging expertise by sharing case study information and uploading the MRI images using Elucirem™ to a secure image portal hosted by appliedradiology.com. By following the important instructions explained below and completing the Elucirem™ MRI Image Submission Form, submitted images will be reviewed by an esteemed Review Committee which includes MRI Thought Leaders and Educators, Applied Radiology Board Members, and Guerbet Associates. The image review process includes assessment of MR images that are only for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.1
1Elucirem [package insert]. Princeton, NJ: Guerbet LLC; 2022
Reward Details & Selection Process
Image of the Month
From the submitted images, an ‘Image of the Month’ will be selected by the review committee. The image of the month will be featured in the monthly Reveal Challenge social media campaign and posted on appliedradiology.com.
Submission Timelines: May ‘23 through Nov ’23.
Image of the Year
One (1) image will be chosen as the Image of the Year and will be revealed at RSNA 2023. The person submitting this image will be invited to join Guerbet at their booth for a special Reveal Event. The announcement of the Image of the Year includes an interview with the winner to be published on appliedradiology.com .
Submission Requirements
To share an Elucirem™ (gadopiclenol) injection MR image, one must read and acknowledge these submission requirements.
Note: The image review process includes assessment of MR images that are only for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.1
Acknowledgement & Release
By sharing the images and case information, you confirm that you have not included identifiable patient information, you are permitted or have the right to provide such images and case information, and hereby grant Applied Radiology and Guerbet LLC* worldwide, royalty-free, sublicensable, transferrable, non-exclusive, perpetual right to use, reproduce, modify, prepare derivative works, and display or publish such images and information for any lawful purposes, whether scientific, educational or promotional.
*”Guerbet LLC” includes its respective parents, affiliates, subsidiaries, licensees, successors, and assigns and any authorized representative of any Guerbet entity (including its affiliates, subsidiaries, successor, or assigns, consultants, vendors, or contractors).
To order Elucirem™ (gadopiclenol) injection, please contact Guerbet at elucireminfo-us@guerbet.com
Image Submission Guidelines & Parameters
All MRI images must be anonymized. MRI images using Elucirem™ must only be for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.
• Formats: .jpeg, .jpg, .png
• File Size: <10 MB
• Minimum Resolution: 300 DPI
Review Committee

Jeffrey Weinreb, MD Jeffrey Weinreb, MD, FACR, FISMRM, FSABI

Chief, Radiology Services,
Director of MRI Services
Yale New Haven Hospital

Blake Johnson, MD, FACR Blake Johnson, MD, FACR

Medical Director,
Medical Scanning Consultants,
RAYUS Radiology

Donna Roberts, MD, MSDonna Roberts, MD, MS

Professor, Department of Radiology
and Radiological Sciences
Medical University of South Carolina

Bill Faulkner Bill Faulkner, BSRT(R)(MR)(CT), FSMRT,
MRSO (MRSC™),

William Faulkner & Associates

Frank Shellock, PhD, FACR, FACC, FISMRM Frank Shellock, PhD, FACR, FACC, FISMRM

Director of MRI Safety
USC Stevens Neuroimaging and Informatics Institute

Adjunct Clinical Professor of Radiology and Medicine
Keck School of Medicine, University of Southern California
Los Angeles, California

ELUCIREM™ (gadopiclenol) injection Important Safety Information

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
See full prescribing information for complete boxed warning

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.

  • The risk for NSF appears highest among patients with:
    • Chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • Acute kidney injury
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. .
Indications and Usage

ELUCIREM™ (gadopiclenol) injection is indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues), and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

Contraindications

History of hypersensitivity reactions to ELUCIREM

Warnings and Precautions
  • Nephrogenic Systemic Fibrosis: GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease as well as patients with acute kidney injury.
  • Hypersensitivity Reactions: With GBCAs, serious hypersensitivity reactions have occurred. In most cases, initial symptoms occurred within minutes of GBCA administration and resolved with prompt emergency treatment. Before ELUCIREM administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to ELUCIREM.
  • Gadolinium Retention: Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing a GBCA for these patients. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.
  • Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent. Do not exceed the recommended dose.
  • Extravasation and Injection Site Reactions: Injection site reactions such as injection site pain have been reported in the clinical studies with ELUCIREM. Extravasation during ELUCIREM administration may result in tissue irritation. Ensure catheter and venous patency before the injection of ELUCIREM.
  • Interference with Visualization of Lesions Visible with Non-Contrast MRI: As with any GBCA, ELUCIREM may impair the visualization of lesions seen on non-contrast MRI. Therefore, caution should be exercised when Gadopiclenol MRI scans are interpreted without a companion non-contrast MRI scan.
Adverse Reactions:

In clinical trials, the most frequent adverse reactions that occurred in > 0.2% of patients who received ELUCIREM included: injection site pain, headache, nausea, injection site warmth, injection site coldness, dizziness, and localized swelling. Adverse reactions that occurred with a frequency ≤ 0.2% in patients who received 0.05 mmol/kg BW ELUCIREM included: maculopapular rash, vomiting, worsened renal impairment, feeling hot, pyrexia, oral paresthesia, dysgeusia, diarrhea, pruritus, allergic dermatitis, erythema, injection site paresthesia, Cystatin C increase, and blood creatinine increase.

Use in Specific Populations
  • Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. There are no available data on ELUCIREM use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
  • Lactation: There are no data on the presence of ELUCIREM in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is excreted in breast milk.
  • Pediatric Use: The safety and effectiveness of ELUCIREM have not been established in pediatric patients younger than 2 years of age.
  • Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.
  • Renal Impairment: In patients with renal impairment, the exposure of gadopiclenol is increased compared to patients with normal renal function. This may increase the risk of adverse reactions such as nephrogenic systemic fibrosis (NSF). Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. No dose adjustment of ELUCIREM is recommended for patients with renal impairment. ELUCIREM can be removed from the body by hemodialysis

Please see the full Prescribing Information, including the Medication Guide, for additional important safety information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

GU04230047